DGAP-News: Press Release: 4SC expands patent protection for its epigenetic anti-cancer compound 4SC-202 in the USA, China and Hong Kong
(firmenpresse) - DGAP-News: 4SC AG / Key word(s): Miscellaneous
Press Release: 4SC expands patent protection for its epigenetic
anti-cancer compound 4SC-202 in the USA, China and Hong Kong
15.07.2013 / 07:30
---------------------------------------------------------------------
Press Release
4SC expands patent protection for its epigenetic anti-cancer compound
4SC-202 in the USA, China and Hong Kong
Planegg-Martinsried, Germany, 15 July 2013 - 4SC AG (Frankfurt, Prime
Standard: VSC), a discovery and development company of targeted small
molecule drugs for autoimmune diseases and cancer, today announced that the
company has significantly expanded international patent protection for
4SC-202, its second epigenetic anti-cancer compound. The oral agent 4SC-202
- a selective inhibitor of HDAC1, 2, and 3 - inhibits the cellular signal
transduction pathways Hedgehog and Wnt which play a key role in cancer
development and progression. The compound is currently being clinically
investigated in a Phase I trial involving patients with haematological
tumours. The results from this trial are expected to be available in the
second half of 2013.
While the composition-of-matter patent for 4SC-202 was granted in China,
granting is imminent in Hong Kong, according to the patent authorities. The
patents cover the composition of matter of the 4SC-202 compound itself,
pharmaceutical compositions comprising the compound, and its therapeutic
use in cancer and in other therapeutic areas. After having obtained the
composition-of-matter patent for 4SC-202 in the United States, the world's
largest pharmaceutical market, 4SC has now received a 'notification of
allowance' for the patent from the US Patent and Trademark Office covering
certain salts of 4SC-202, among them tosylate salt. This will enable 4SC to
significantly extend the duration of patent protection for 4SC-202 in the
United States.
With sales of prescription drugs exceeding USD 279 billion, the USA are by
far the world's largest pharmaceutical market. According the the IMS Health
information service, China is already the world's third-largest market for
pharmaceuticals behind the USA and Japan with an overall volume of around
USD 50 billion. Analysts forecast strong annual growth of between 18% and
25% for the sector in China by 2020. Furthermore, the oncology market in
Asia will see particularly strong growth and therefore become increasingly
important for the development and marketing of innovative cancer drugs such
as 4SC-202.Today, nearly half of all new cancer cases worldwide already
occur in Asia.
'Strengthening patent protection for our innovative anti-cancer compound
4SC-202 in the key markets of the United States and China underscores the
development strategy for 4SC-202,' commented Enno Spillner, CEO of 4SC AG.
'In achieving this enhanced protection, we further strengthen our position
as a leading biotech company in epigenetic cancer drugs.'
Enno Spillner continued: 'Alongside our epigenetic value driver
resminostat, 4SC-202 is the second promising epigenetic anti-cancer
compound we have in clinical development. While our primary focus with
resminostat is achieving market approval for the compound in combination
therapy with conventional anti-cancer drugs for solid tumours such as liver
cancer, we believe 4SC-202's mechanism of action gives it major potential
as a standalone treatment for haematological tumours, whose development and
progression depends heavily on the Hedgehog and Wnt signalling pathways,
which are of great therapeutic interest.'
Ends
About 4SC-202
In addition to resminostat, 4SC-202 is 4SC's second epigenetic drug
candidate in clinical development. 4SC-202 is an orally administered
selective inhibitor of HDAC1, 2, and 3 with a unique combination of
anti-cancer mode of actions, namely epigenetic regulation and targeting of
cancer stem cells. 4SC-202 has been shown to inhibit the Hedgehog and Wnt
signalling pathways in cancer cells via epigenetic modifications, thereby
provoking the inhibition of properties of cancer stem cells. The Hedgehog
and Wnt signalling pathways play an important role in cancer development
and progression. Currently 4SC-202, which has already shown good efficacy
in preclinical in vivo models, is being investigated in a Phase I clinical
study in patients with advanced haematological tumours.
About 4SC
The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops
targeted, small-molecule drugs for treating diseases with high unmet
medical needs in cancer and autoimmune indications. These drugs are
intended to provide innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The Company's pipeline comprises promising products that are in
various stages of clinical development. 4SC's aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
pharmaceutical and biotech companies. Founded in 1997, 4SC had 83 employees
at 30 June 2013. 4SC AG has been listed on the Prime Standard of the
Frankfurt Stock Exchange since December 2005.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
For more information please visit www.4sc.com or contact:
4SC AG
Jochen Orlowski, Corporate Communications&Investor Relations
jochen.orlowski(at)4sc.com, Tel.: +49-89-7007-6366
MC Services
Raimund Gabriel
raimund.gabriel(at)mc-services.eu , Tel.: +49-89-2102-2830
The Trout Group (USA)
Chad Rubin
Crubin(at)troutgroup.com, Tel.: +1-646-378-2947
End of Corporate News
---------------------------------------------------------------------
15.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public(at)4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
220955 15.07.2013
Themen in dieser Pressemitteilung:
press-release-4sc-expands-patent-protection-for-its-epigenetic-anti
cancer-compound-4sc
202-in-the-usa
china-and-hong-kong
Unternehmensinformation / Kurzprofil:
Datum: 15.07.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 278116
Anzahl Zeichen: 8742
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 297 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Press Release: 4SC expands patent protection for its epigenetic anti-cancer compound 4SC-202 in the USA, China and Hong Kong"
steht unter der journalistisch-redaktionellen Verantwortung von
4SC AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
